A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America
Authors:
- Benedito Mauro RossiBRBenedito Mauro Rossi
- Edenir Inêz PalmeroEPEdenir Inêz Palmero
- Francisco López-KostnerFLFrancisco López-Kostner
- Carlos SarrocaCSCarlos Sarroca
- Carlos Alberto VaccaroCVCarlos Alberto Vaccaro
- Florencia SpirandelliFSFlorencia Spirandelli
- Patricia Ashton-ProllaPAPatricia Ashton-Prolla
- Yenni RodriguezYRYenni Rodriguez
- Henrique de Campos Reis GalvãoHGHenrique de Campos Reis Galvão
- Rui Manuel ReisRui Manuel Reis
- André Escremim de PaulaAPAndré Escremim de Paula
- Luis Gustavo Capochin RomagnoloLRLuis Gustavo Capochin Romagnolo
Open Access
- 5 September 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-26
Abstract
Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome. We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet. The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.Keywords
Funding Information
- Radium Hospital
- French Association Recherche contre le Cancer
- Helse Sør-Øst RHF
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
- Association Nationale de la Recherche et de la Technologie
- OpenHealth Institute
This publication has 87 references indexed in Scilit:
- Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsHuman Mutation, 2012
- Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countriesBMC Cancer, 2012
- Identification of patients at-risk for Lynch syndrome in a hospital-based colorectal surgery clinicWorld Journal of Gastroenterology, 2011
- Microsatellite instability among individuals of Hispanic origin with colorectal cancerCancer, 2010
- Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto RicoFamilial Cancer, 2009
- Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relativesGenetics in Medicine, 2009
- Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: A cost-effectiveness analysisEuropean Journal of Cancer, 2008
- Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing SignalsJournal of Computational Biology, 2004
- Life‐time risk of different cancers in hereditary non‐polyposis colorectal cancer (hnpcc) syndromeInternational Journal of Cancer, 1995
- The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)Diseases of the Colon & Rectum, 1991